Alpine Immune Sciences, Inc. (NasdaqGM: ALPN)
Health Care · Biotechnology · US
$—
— today · — 1Y
Alpine Immune Sciences, Inc. (NasdaqGM: ALPN) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Alpine Immune Sciences, Inc. across four factors: quality 38/100, growth 100/100. Its strongest factor is growth.
ALPN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $56.52M
- P/E
- —
- EPS
- -0.68
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 142
- Next earnings
- —
About Alpine Immune Sciences, Inc.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
- ISIN
- US02083G1004
- Founded
- 2007
- Listed since
- Jun 17, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.04 | +0.03% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $442.05 | +0.62% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.34 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | 0.00% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $827.71 | -0.76% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $140.59 | -3.09% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.